Apart from the local adverse effects of these agents, the important limitation is the localization of their effect to the site of application alone
In the world of peptides, few compounds are as hyped or as controversial as BPC-157
Some patients are still clearly able to get these drugs
Its important to note that there are few studies involving calcium alone for the treatment of migraine
10.1111/j.1364-3703.2007.00387.x 143 SellamA.PoupardP.SimoneauP

[31] A large study found that GLP-1 RA use was associated with lower risk of developing immune-mediated inflammatory diseases in patients with type 2 diabetes or obesity, suggesting a potential protective effect in some cohorts.[42] What the science is showing is potential for improvements: GLP-1RAs reduce blunt activation in fibroblast-like synoviocytes and improve joint inflammation and metabolic parameters in rheumatoid arthritis models and small human cohorts.[26][29][25] [31] Early clinical studies and case series in RA patients (especially those with coexisting type 2 diabetes or obesity) reported reduced disease activity scores (DAS28), lower C-reactive protein and erythrocyte sedimentation rate levels, fewer swollen joints, and diminished morning stiffness during GLP-1RA treatment, along with the expected weight reduction and improved insulin sensitivity.[31] Psoriasis showed improved PASI scores and quality-of-life metrics in patients with T2DM and psoriasis, alongside reductions in lesional skin and peripheral TNF-producing monocytes.[26] Case series show meaningful skin improvement.[26] In psoriasis and psoriatic arthritis , GLP-1RA therapy has been associated with improvements in inflammatory markers and disease severity indices
